Decreasing Seizure Treatment Time Through Quality Improvement Reduces Critical Care Utilization.

Pediatr Neurol

Neurology Division, Department of Pediatrics, The Ohio State University, Columbus, Ohio; Nationwide Children's Hospital, Columbus, Ohio.

Published: August 2018

Background: Rapid, effective treatment for status epilepticus reduces associated morbidity and mortality, yet medication delivery remains slow in many hospitalized patients. We utilized quality improvement (QI) methodology to improve treatment times for hospitalized children with status epilepticus. We hypothesized rapid initial seizure treatment would decrease seizure morbidity.

Methods: We utilized QI and statistical process control analysis in a nonintensive care setting within a tertiary care pediatric hospital. We performed Plan-Do-Study-Act cycles including (1) revising the nursing process for responding to seizures, (2) emphasizing intranasal midazolam over intravenous lorazepam, (3) relocating medications and supplies, (4) developing documentation tools and reinforcing correct processes, (5) developing and disseminating an online education module for residents and nurse practitioners, and (6) completing standardization to intranasal midazolam.

Results: Seventeen months after starting the project, 66 seizures had been treated with a benzodiazepine in a median (p-p) time of 7.5 minutes (5 to 10), decreased from a baseline of 14 minutes (8-30) (P = 0.01). The proportion of patients receiving a benzodiazepine in 10 minutes or less improved from 39% to 79%. The proportion of patients transferred to intensive care decreased from a baseline of 39% to 9% (P < 0.005), resulting in an estimated $2.1 million in mitigated hospital charges. Significant harm did not occur during the implementation of these interventions.

Conclusions: Children with status epilepticus were treated with benzodiazepines more rapidly and effectively following implementation of QI methodology. These interventions reduced utilization of critical care and mitigated hospital charges.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pediatrneurol.2018.05.012DOI Listing

Publication Analysis

Top Keywords

status epilepticus
12
seizure treatment
8
quality improvement
8
critical care
8
children status
8
decreased baseline
8
proportion patients
8
mitigated hospital
8
hospital charges
8
care
5

Similar Publications

Background: Epileptiform activity, including status epilepticus (SE), occurs in up to one-third of comatose survivors of cardiac arrest and may predict poor outcome. The relationship between SE and hypoxic-ischemic brain injury (HIBI) is not established.

Methods: This is a single-center retrospective study on consecutive patients with post-anoxic super-refractory SE.

View Article and Find Full Text PDF

Management of Status Epilepticus and Infections in a Patient with Lennox Gastaut Syndrome.

Can J Hosp Pharm

January 2025

BMSc, MD, FRCPC, is with the Department of Critical Care Medicine, Alberta Health Services, and the Departments of Critical Care Medicine and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta.

View Article and Find Full Text PDF

Management of epilepsia partialis continua: A systematic review.

Seizure

January 2025

University of Adelaide, Adelaide SA 5005, Australia; Flinders University, Bedford Park SA 5042, Australia; Lyell McEwin Hospital, Elizabeth Vale SA 5112, Australia; Department of Neurology and the Center for Genomic Medicine, Massachusetts General Hospital and Harvard Medical School, Boston MA 02138, USA.

Purpose: Epilepsia partialis continua (EPC) is form of focal motor status epilepticus, with limited guidelines regarding effective pharmacological management. This systematic review aimed to describe previously utilized pharmacological management strategies for EPC, with a focus on patient outcomes.

Methods: A systematic review of the databases PubMed, EMBASE, and SCOPUS was performed from inception to May 2024.

View Article and Find Full Text PDF

Child Neurology: Severe -Related Congenital Muscular Dystrophy With Rapidly Progressive Encephalopathy Leading to Infantile Death.

Neurology

February 2025

Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Ontario, Canada.

Pathogenic variants in cause congenital muscular dystrophy through hypoglycosylation of alpha-dystroglycan (OMIM #615350). The established phenotypic spectrum of GMPPB-related disorders includes recurrent rhabdomyolysis, limb-girdle muscular dystrophy, neuromuscular transmission abnormalities, and congenital muscular dystrophy with variable brain and eye anomalies. We report a 9-month-old male infant with congenital muscular dystrophy, infantile spasms, and compound heterozygous pathogenic variants (c.

View Article and Find Full Text PDF

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the respiratory system, neurological symptoms were reported both during acute and post-acute COVID-19. Notably, patients with no history of epilepsy or other neurological conditions developed new-onset refractory status epilepticus (NORSE) weeks, months, or even up to a year following the viral infection. While NORSE is uncommon, it carries a high mortality rate and can result in permanent epilepsy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!